Connection

LAWRENCE DONEHOWER to Animals

This is a "connection" page, showing publications LAWRENCE DONEHOWER has written about Animals.
Connection Strength

1.042
  1. Enhanced inflammation and attenuated tumor suppressor pathways are associated with oncogene-induced lung tumors in aged mice. Aging Cell. 2018 02; 17(1).
    View in: PubMed
    Score: 0.033
  2. Insights into wild-type and mutant p53 functions provided by genetically engineered mice. Hum Mutat. 2014 Jun; 35(6):715-27.
    View in: PubMed
    Score: 0.026
  3. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses. Mol Cancer Res. 2012 Jun; 10(6):845-55.
    View in: PubMed
    Score: 0.023
  4. Absence of Wip1 partially rescues Atm deficiency phenotypes in mice. Oncogene. 2012 Mar 01; 31(9):1155-65.
    View in: PubMed
    Score: 0.022
  5. The oncogenic phosphatase WIP1 negatively regulates nucleotide excision repair. DNA Repair (Amst). 2010 Jul 01; 9(7):813-23.
    View in: PubMed
    Score: 0.020
  6. Wild-type p53-induced phosphatase 1 dephosphorylates histone variant gamma-H2AX and suppresses DNA double strand break repair. J Biol Chem. 2010 Apr 23; 285(17):12935-47.
    View in: PubMed
    Score: 0.019
  7. Using mice to examine p53 functions in cancer, aging, and longevity. Cold Spring Harb Perspect Biol. 2009 Dec; 1(6):a001081.
    View in: PubMed
    Score: 0.019
  8. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer. 2009 11; 9(11):831-41.
    View in: PubMed
    Score: 0.019
  9. Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS One. 2009 Aug 14; 4(8):e6654.
    View in: PubMed
    Score: 0.019
  10. Altered senescence, apoptosis, and DNA damage response in a mutant p53 model of accelerated aging. Mech Ageing Dev. 2009 Apr; 130(4):262-71.
    View in: PubMed
    Score: 0.018
  11. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res. 2009 Mar 15; 69(6):2559-67.
    View in: PubMed
    Score: 0.018
  12. Longevity regulation in flies: a role for p53. Aging (Albany NY). 2009 Jan 10; 1(1):6-8.
    View in: PubMed
    Score: 0.018
  13. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 2008 Jun; 27(2):123-35.
    View in: PubMed
    Score: 0.017
  14. How does suppression of IGF-1 signaling by DNA damage affect aging and longevity? Mech Ageing Dev. 2008 May; 129(5):243-53.
    View in: PubMed
    Score: 0.017
  15. The Wip1 phosphatase and Mdm2: cracking the "Wip" on p53 stability. Cell Cycle. 2008 Jan 15; 7(2):164-8.
    View in: PubMed
    Score: 0.017
  16. Decline and fall of the tumor suppressor. Proc Natl Acad Sci U S A. 2007 Nov 20; 104(47):18347-8.
    View in: PubMed
    Score: 0.017
  17. Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity. Mech Ageing Dev. 2007 Nov-Dec; 128(11-12):717-30.
    View in: PubMed
    Score: 0.017
  18. Altered mammary gland development in the p53+/m mouse, a model of accelerated aging. Dev Biol. 2008 Jan 01; 313(1):130-41.
    View in: PubMed
    Score: 0.017
  19. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell. 2007 Oct; 12(4):342-54.
    View in: PubMed
    Score: 0.017
  20. Tumor suppressor dosage regulates stem cell dynamics during aging. Cell Cycle. 2007 Jan 01; 6(1):52-5.
    View in: PubMed
    Score: 0.016
  21. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood. 2007 Feb 15; 109(4):1736-42.
    View in: PubMed
    Score: 0.015
  22. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Mol Carcinog. 2006 Aug; 45(8):594-604.
    View in: PubMed
    Score: 0.015
  23. The utility of genetically altered mouse models for cancer research. Mutat Res. 2005 Aug 25; 576(1-2):1-3.
    View in: PubMed
    Score: 0.014
  24. Probing p53 biological functions through the use of genetically engineered mouse models. Mutat Res. 2005 Aug 25; 576(1-2):4-21.
    View in: PubMed
    Score: 0.014
  25. Homeostatic regulation of base excision repair by a p53-induced phosphatase: linking stress response pathways with DNA repair proteins. Cell Cycle. 2004 Nov; 3(11):1363-6.
    View in: PubMed
    Score: 0.014
  26. The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Mol Cell. 2004 Aug 27; 15(4):621-34.
    View in: PubMed
    Score: 0.013
  27. Insights into aging obtained from p53 mutant mouse models. Ann N Y Acad Sci. 2004 Jun; 1019:171-7.
    View in: PubMed
    Score: 0.013
  28. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis. Oncogene. 2003 Oct 30; 22(49):7831-7.
    View in: PubMed
    Score: 0.013
  29. Functional analysis of tumor suppressor genes in mice. Methods Mol Biol. 2003; 223:283-314.
    View in: PubMed
    Score: 0.012
  30. Does p53 affect organismal aging? J Cell Physiol. 2002 Jul; 192(1):23-33.
    View in: PubMed
    Score: 0.012
  31. K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications. Dis Model Mech. 2022 02 01; 15(2).
    View in: PubMed
    Score: 0.011
  32. Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol Cell Biol. 2002 Feb; 22(4):1094-105.
    View in: PubMed
    Score: 0.011
  33. p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002 Jan 03; 415(6867):45-53.
    View in: PubMed
    Score: 0.011
  34. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing. Toxicol Pathol. 2001; 29 Suppl:147-54.
    View in: PubMed
    Score: 0.010
  35. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol Pathol. 2001; 29 Suppl:24-9.
    View in: PubMed
    Score: 0.010
  36. Differential gene expression in mouse mammary adenocarcinomas in the presence and absence of wild type p53. Oncogene. 2000 Dec 07; 19(52):5988-96.
    View in: PubMed
    Score: 0.010
  37. Effect of intragastric application of N-methylnitrosourea in p53 knockout mice. Mol Carcinog. 2000 Jun; 28(2):97-101.
    View in: PubMed
    Score: 0.010
  38. The structure and expression of the murine wildtype p53-induced phosphatase 1 (Wip1) gene. Genomics. 2000 Mar 15; 64(3):298-306.
    View in: PubMed
    Score: 0.010
  39. Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Cell Growth Differ. 1999 Apr; 10(4):213-22.
    View in: PubMed
    Score: 0.009
  40. Increased tumor cell proliferation in murine tumors with decreasing dosage of wild-type p53. Mol Carcinog. 1999 Mar; 24(3):197-208.
    View in: PubMed
    Score: 0.009
  41. p53 in embryonic development: maintaining a fine balance. Cell Mol Life Sci. 1999 Jan; 55(1):38-47.
    View in: PubMed
    Score: 0.009
  42. Mouse models in tumor suppression. Oncogene. 1998 Dec 24; 17(25):3385-400.
    View in: PubMed
    Score: 0.009
  43. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell. 2018 11 01; 23(5):700-713.e6.
    View in: PubMed
    Score: 0.009
  44. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 1998 Aug 17; 17(16):4657-67.
    View in: PubMed
    Score: 0.009
  45. Murine tumor suppressor models. Mutat Res. 1998 May 25; 400(1-2):391-407.
    View in: PubMed
    Score: 0.009
  46. miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma. Int J Cancer. 2017 11 15; 141(10):2062-2075.
    View in: PubMed
    Score: 0.008
  47. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ. 1997 Aug; 8(8):829-38.
    View in: PubMed
    Score: 0.008
  48. Genetic instability in animal tumorigenesis models. Cancer Surv. 1997; 29:329-52.
    View in: PubMed
    Score: 0.008
  49. Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential. BMC Cancer. 2016 11 08; 16(1):869.
    View in: PubMed
    Score: 0.008
  50. The p53-deficient mouse: a model for basic and applied cancer studies. Semin Cancer Biol. 1996 Oct; 7(5):269-78.
    View in: PubMed
    Score: 0.008
  51. Effects of p53 mutation on tumor progression: recent insights from mouse tumor models. Biochim Biophys Acta. 1996 Mar 18; 1242(3):171-6.
    View in: PubMed
    Score: 0.007
  52. The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model. Prog Clin Biol Res. 1996; 395:1-11.
    View in: PubMed
    Score: 0.007
  53. Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis. Br J Cancer. 2015 Nov 03; 113(9):1289-97.
    View in: PubMed
    Score: 0.007
  54. Coamplification of Myc/Pvt1 and homozygous deletion of Nlrp1 locus are frequent genetics changes in mouse osteosarcoma. Genes Chromosomes Cancer. 2015 Dec; 54(12):796-808.
    View in: PubMed
    Score: 0.007
  55. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog. 1995 Sep; 14(1):16-22.
    View in: PubMed
    Score: 0.007
  56. Ghrelin Prevents Cisplatin-Induced Testicular Damage by Facilitating Repair of DNA Double Strand Breaks Through Activation of p53 in Mice. Biol Reprod. 2015 Jul; 93(1):24.
    View in: PubMed
    Score: 0.007
  57. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev. 1995 Apr 01; 9(7):882-95.
    View in: PubMed
    Score: 0.007
  58. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015 Jul; 4(7):977-88.
    View in: PubMed
    Score: 0.007
  59. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet. 1995 Mar; 9(3):305-11.
    View in: PubMed
    Score: 0.007
  60. Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res. 1995 Mar 01; 55(5):1146-51.
    View in: PubMed
    Score: 0.007
  61. NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. Oncogene. 2015 Sep 24; 34(39):5069-79.
    View in: PubMed
    Score: 0.007
  62. Notch activation as a driver of osteogenic sarcoma. Cancer Cell. 2014 Sep 08; 26(3):390-401.
    View in: PubMed
    Score: 0.007
  63. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):11145-50.
    View in: PubMed
    Score: 0.007
  64. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet. 1993 Nov; 5(3):225-9.
    View in: PubMed
    Score: 0.006
  65. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene. 1993 Sep; 8(9):2457-67.
    View in: PubMed
    Score: 0.006
  66. The tumor suppressor p53. Biochim Biophys Acta. 1993 Aug 23; 1155(2):181-205.
    View in: PubMed
    Score: 0.006
  67. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 1993 Jul; 7(10):938-43.
    View in: PubMed
    Score: 0.006
  68. REG? deficiency promotes premature aging via the casein kinase 1 pathway. Proc Natl Acad Sci U S A. 2013 Jul 02; 110(27):11005-10.
    View in: PubMed
    Score: 0.006
  69. Transcriptional and translational regulation of C/EBP?-HDAC1 protein complexes controls different levels of p53, SIRT1, and PGC1a proteins at the early and late stages of liver cancer. J Biol Chem. 2013 May 17; 288(20):14451-14462.
    View in: PubMed
    Score: 0.006
  70. Activation of WIP1 phosphatase by HTLV-1 Tax mitigates the cellular response to DNA damage. PLoS One. 2013; 8(2):e55989.
    View in: PubMed
    Score: 0.006
  71. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992 Mar 19; 356(6366):215-21.
    View in: PubMed
    Score: 0.006
  72. Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models. J Pathol. 2011 Aug; 224(4):540-52.
    View in: PubMed
    Score: 0.005
  73. Mdm2-p53 signaling regulates epidermal stem cell senescence and premature aging phenotypes in mouse skin. Dev Biol. 2011 May 01; 353(1):1-9.
    View in: PubMed
    Score: 0.005
  74. P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res Treat. 2011 Nov; 130(2):399-408.
    View in: PubMed
    Score: 0.005
  75. Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS One. 2010 Jun 07; 5(6):e10995.
    View in: PubMed
    Score: 0.005
  76. Impact papers on aging in 2009. Aging (Albany NY). 2010 Mar; 2(3):111-21.
    View in: PubMed
    Score: 0.005
  77. Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res. 2010 Mar; 20(3):332-40.
    View in: PubMed
    Score: 0.005
  78. Exercise effects on tumorigenesis in a p53-deficient mouse model of breast cancer. Med Sci Sports Exerc. 2009 Aug; 41(8):1597-605.
    View in: PubMed
    Score: 0.005
  79. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet. 2009 Apr 15; 18(8):1464-70.
    View in: PubMed
    Score: 0.005
  80. Identification of a conserved sequence in the non-coding regions of many human genes. Nucleic Acids Res. 1989 Jan 25; 17(2):699-710.
    View in: PubMed
    Score: 0.005
  81. Analysis of mutant Moloney murine leukemia viruses containing linker insertion mutations in the 3' region of pol. J Virol. 1988 Nov; 62(11):3958-64.
    View in: PubMed
    Score: 0.004
  82. Early development of histiocytic sarcomas in p53 knockout mice treated with N-bis(2-hydroxypropyl)nitrosamine. Oncol Rep. 2007 Oct; 18(4):755-61.
    View in: PubMed
    Score: 0.004
  83. Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. PLoS Biol. 2007 Aug; 5(8):e201.
    View in: PubMed
    Score: 0.004
  84. Organ-dependent susceptibility of p53 knockout mice to 2-amino-3-methylimidazo[4,5-f]quinoline (IQ). Cancer Sci. 2007 Aug; 98(8):1164-73.
    View in: PubMed
    Score: 0.004
  85. Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res. 2007 May 01; 67(9):4104-12.
    View in: PubMed
    Score: 0.004
  86. DeltaNp63alpha overexpression induces downregulation of Sirt1 and an accelerated aging phenotype in the mouse. Cell Cycle. 2006 Sep; 5(17):2005-11.
    View in: PubMed
    Score: 0.004
  87. Oxidative and nitrative stress caused by subcutaneous implantation of a foreign body accelerates sarcoma development in Trp53+/- mice. Carcinogenesis. 2007 Jan; 28(1):191-8.
    View in: PubMed
    Score: 0.004
  88. Oncogenic function for the Dlg1 mammalian homolog of the Drosophila discs-large tumor suppressor. EMBO J. 2006 Mar 22; 25(6):1406-17.
    View in: PubMed
    Score: 0.004
  89. Organ-specific susceptibility of p53 knockout mice to N-bis(2-hydroxypropyl)nitrosamine carcinogenesis. Cancer Lett. 2006 Jul 18; 238(2):271-83.
    View in: PubMed
    Score: 0.004
  90. Analysis of cellular senescence in culture in vivo: the senescence-associated beta-galactosidase assay. Curr Protoc Cell Biol. 2005 Jul; Chapter 18:18.9.1-18.9.9.
    View in: PubMed
    Score: 0.004
  91. Lack of elevated liver carcinogenicity of aminophenylnorharman in p53-deficient mice. Cancer Lett. 2005 Jan 20; 217(2):149-59.
    View in: PubMed
    Score: 0.003
  92. Suppression of thymic lymphomas and increased nonthymic lymphomagenesis in Trp53-deficient mice lacking inducible nitric oxide synthase gene. Int J Cancer. 2004 Oct 10; 111(6):819-28.
    View in: PubMed
    Score: 0.003
  93. Diet-gene interactions in p53-deficient mice: insulin-like growth factor-1 as a mechanistic target. J Nutr. 2004 Sep; 134(9):2482S-2486S.
    View in: PubMed
    Score: 0.003
  94. Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain. Cancer Res. 2004 Aug 01; 64(15):5140-7.
    View in: PubMed
    Score: 0.003
  95. Transgenic tumor models for carcinogen identification: the heterozygous Trp53-deficient and RasH2 mouse lines. Mutat Res. 2003 Oct 07; 540(2):165-76.
    View in: PubMed
    Score: 0.003
  96. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol. 2003 Sep; 23(17):6159-73.
    View in: PubMed
    Score: 0.003
  97. High susceptibility of nullizygous p53 knockout mice to colorectal tumor induction by 1,2-dimethylhydrazine. J Cancer Res Clin Oncol. 2003 Jun; 129(6):335-40.
    View in: PubMed
    Score: 0.003
  98. Generation and characterization of p53 mutant mice. Methods Mol Biol. 2003; 234:29-49.
    View in: PubMed
    Score: 0.003
  99. Elevated susceptibility of the p53 knockout mouse esophagus to methyl-N-amylnitrosamine carcinogenesis. Carcinogenesis. 2002 Sep; 23(9):1541-7.
    View in: PubMed
    Score: 0.003
  100. Visual genotyping of a coat color tagged p53 mutant mouse line. Cancer Biol Ther. 2002 Jul-Aug; 1(4):433-5.
    View in: PubMed
    Score: 0.003
  101. Cancer prevention studies in p53-deficient mice. Toxicol Pathol. 2001 Jan-Feb; 29(1):137-41.
    View in: PubMed
    Score: 0.003
  102. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem. 2000 Oct 20; 275(42):32649-57.
    View in: PubMed
    Score: 0.003
  103. p53 knockout mice (-/-) are more susceptible than (+/-) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis. Carcinogenesis. 2000 Oct; 21(10):1891-7.
    View in: PubMed
    Score: 0.003
  104. Cooperation between Ha-ras and fos or transforming growth factor alpha overcomes a paradoxic tumor-inhibitory effect of p53 loss in transgenic mouse epidermis. Mol Carcinog. 2000 Oct; 29(2):67-75.
    View in: PubMed
    Score: 0.003
  105. Absence of p53: no effect in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp Neurol. 2000 Sep; 165(1):184-90.
    View in: PubMed
    Score: 0.003
  106. Reduction in p53 gene dosage diminishes differentiation capacity of osteoblasts. Anticancer Res. 2000 Jul-Aug; 20(4):2553-9.
    View in: PubMed
    Score: 0.003
  107. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 2000 Jun 15; 14(12):1448-59.
    View in: PubMed
    Score: 0.002
  108. Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: evidence of chromosomal recombination. Cancer Res. 2000 Jun 01; 60(11):2831-5.
    View in: PubMed
    Score: 0.002
  109. Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci U S A. 2000 Mar 28; 97(7):3461-6.
    View in: PubMed
    Score: 0.002
  110. Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression. Oncogene. 2000 Mar 23; 19(13):1635-46.
    View in: PubMed
    Score: 0.002
  111. Construction and characterization of molecular clones containing integrated mouse mammary tumor virus sequences. Cold Spring Harb Symp Quant Biol. 1980; 44 Pt 2,:1153-9.
    View in: PubMed
    Score: 0.002
  112. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998 Dec 22; 95(26):15608-12.
    View in: PubMed
    Score: 0.002
  113. Decreased immunoglobulin deposition in tumors and increased immature B cells in p53-null mice. Cell Growth Differ. 1997 Feb; 8(2):121-31.
    View in: PubMed
    Score: 0.002
  114. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc Natl Acad Sci U S A. 1996 Nov 26; 93(24):14106-11.
    View in: PubMed
    Score: 0.002
  115. Genomic organization of the mouse double minute 2 gene. Gene. 1996 Oct 10; 175(1-2):209-13.
    View in: PubMed
    Score: 0.002
  116. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha. Cancer Res. 1996 Oct 01; 56(19):4413-23.
    View in: PubMed
    Score: 0.002
  117. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol Cell Biol. 1996 Jul; 16(7):3765-72.
    View in: PubMed
    Score: 0.002
  118. Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development? J Virol. 1996 Apr; 70(4):2095-100.
    View in: PubMed
    Score: 0.002
  119. p53 is required for both radiation-induced differentiation and rescue of V(D)J rearrangement in scid mouse thymocytes. Genes Dev. 1996 Mar 01; 10(5):553-65.
    View in: PubMed
    Score: 0.002
  120. Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death. J Neurosci. 1996 Feb 15; 16(4):1337-45.
    View in: PubMed
    Score: 0.002
  121. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995 Nov 09; 378(6553):206-8.
    View in: PubMed
    Score: 0.002
  122. Transgenic mouse models for tumour-suppressor genes. J Intern Med. 1995 Sep; 238(3):233-8.
    View in: PubMed
    Score: 0.002
  123. p53 deficiency does not affect the accumulation of point mutations in a transgene target. Proc Natl Acad Sci U S A. 1995 Aug 29; 92(18):8517-21.
    View in: PubMed
    Score: 0.002
  124. Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol. 1995 Aug; 15(8):4249-59.
    View in: PubMed
    Score: 0.002
  125. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene. 1995 Jul 06; 11(1):181-90.
    View in: PubMed
    Score: 0.002
  126. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene. 1995 May 04; 10(9):1717-23.
    View in: PubMed
    Score: 0.002
  127. Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res. 1995 May 01; 55(9):1963-70.
    View in: PubMed
    Score: 0.002
  128. Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene. 1995 Apr 06; 10(7):1269-74.
    View in: PubMed
    Score: 0.002
  129. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene. 1995 Mar 02; 10(5):869-79.
    View in: PubMed
    Score: 0.002
  130. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene. 1994 Dec; 9(12):3731-6.
    View in: PubMed
    Score: 0.002
  131. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene. 1994 Nov; 9(11):3107-12.
    View in: PubMed
    Score: 0.002
  132. Gene-targeting and the p53 tumor-suppressor gene. Mutat Res. 1994 Jun 01; 307(2):557-72.
    View in: PubMed
    Score: 0.002
  133. Infrequent p53 mutations in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in BALB/c and p53 hemizygous mice. Mol Carcinog. 1994 Mar; 9(3):175-83.
    View in: PubMed
    Score: 0.002
  134. Transgenic animals in toxicology. Fundam Appl Toxicol. 1994 Jan; 22(1):8-19.
    View in: PubMed
    Score: 0.002
  135. Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proc Natl Acad Sci U S A. 1993 Oct 01; 90(19):9075-9.
    View in: PubMed
    Score: 0.002
  136. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell. 1993 Sep 10; 74(5):813-22.
    View in: PubMed
    Score: 0.002
  137. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther. 1993 Aug; 4(4):451-60.
    View in: PubMed
    Score: 0.002
  138. Retroviral DNA integrated during infection by an integration-deficient mutant of murine leukemia virus is oligomeric. J Virol. 1987 Jun; 61(6):1964-71.
    View in: PubMed
    Score: 0.001
  139. Sequence comparison in the crossover region of an oncogenic avian retrovirus recombinant and its nononcogenic parent: genetic regions that control growth rate and oncogenic potential. Mol Cell Biol. 1982 Nov; 2(11):1331-8.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.